Kullman notched a major (and rare) win against an activist in May when her share­holders voted down Nelson Peltz’s proxy fight to split up DuPont and nominate his candidates to its board. Still, you can’t fault his attempt to shake things up; revenue declined slightly last year to $36 billion, while profits sank 25% to $3.6 billion. The chemicals conglomerate took a page from Peltz’s playbook when it spun off its Chemours subsidiary in July. Kullman maintains it was her own idea all along.